Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
03 janv. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer’s Disease
20 avr. 2016 07h00 HE
|
Axsome Therapeutics, Inc.
Phase 2/3 Trial Planned in Agitation in Alzheimer’s DiseaseIND Submission Expected in 2016 NEW YORK, April 20, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage...